Cargando…
Primaquine in vivax malaria: an update and review on management issues
Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax...
Autores principales: | Fernando, Deepika, Rodrigo, Chaturaka, Rajapakse, Senaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306765/ https://www.ncbi.nlm.nih.gov/pubmed/22152065 http://dx.doi.org/10.1186/1475-2875-10-351 |
Ejemplares similares
-
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
por: Rajapakse, Senaka, et al.
Publicado: (2015) -
Pharmacological management of tetanus: an evidence-based review
por: Rodrigo, Chaturaka, et al.
Publicado: (2014) -
Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?
por: Rodrigo, Chaturaka, et al.
Publicado: (2020) -
Current Evidence on the Use of Antifilarial Agents in the Management of Bancroftian Filariasis
por: Fernando, Sumadhya Deepika, et al.
Publicado: (2011) -
The 'hidden' burden of malaria: cognitive impairment following infection
por: Fernando, Sumadhya D, et al.
Publicado: (2010)